Gilead Sciences, Inc. (NASDAQ:GILD) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have been given an average rating of “Moderate Buy” by the twenty-nine analysts that are currently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and twenty-six have given a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $159.0370.

A number of analysts recently issued reports on GILD shares. Daiwa Securities Group dropped their price target on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, May 19th. Rothschild & Co Redburn reduced their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Royal Bank Of Canada dropped their target price on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a research report on Tuesday, July 7th. Finally, Weiss Ratings lowered shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, May 28th.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $123.92, for a total transaction of $371,760.00. Following the transaction, the insider owned 124,234 shares of the company’s stock, valued at $15,395,077.28. This trade represents a 2.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total value of $1,894,350.00. Following the transaction, the chief executive officer directly owned 607,133 shares in the company, valued at approximately $76,674,826.57. This represents a 2.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 77,000 shares of company stock worth $9,978,740 over the last quarter. 0.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Gilead Sciences

A number of hedge funds have recently added to or reduced their stakes in the business. Bank & Trust Co increased its stake in Gilead Sciences by 4.3% during the second quarter. Bank & Trust Co now owns 6,090 shares of the biopharmaceutical company’s stock valued at $769,000 after purchasing an additional 249 shares during the last quarter. Tema ETFs LLC raised its holdings in shares of Gilead Sciences by 0.7% during the second quarter. Tema ETFs LLC now owns 57,158 shares of the biopharmaceutical company’s stock worth $7,221,000 after purchasing an additional 415 shares during the period. Fiduciary Financial Group LLC bought a new position in shares of Gilead Sciences in the 2nd quarter worth about $226,000. Generali Investments Management Co LLC lifted its position in shares of Gilead Sciences by 31.8% in the 2nd quarter. Generali Investments Management Co LLC now owns 20,496 shares of the biopharmaceutical company’s stock worth $2,589,000 after buying an additional 4,941 shares during the last quarter. Finally, Shrier Wealth Management LLC boosted its holdings in shares of Gilead Sciences by 1.0% in the 2nd quarter. Shrier Wealth Management LLC now owns 14,201 shares of the biopharmaceutical company’s stock valued at $1,794,000 after buying an additional 135 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $134.28 on Monday. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. Gilead Sciences has a fifty-two week low of $107.75 and a fifty-two week high of $157.29. The business has a 50 day moving average price of $129.73 and a two-hundred day moving average price of $135.30. The firm has a market cap of $166.72 billion, a PE ratio of 18.29 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.Gilead Sciences’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts expect that Gilead Sciences will post -0.77 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were issued a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend was Monday, June 15th. Gilead Sciences’s payout ratio is currently 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.